Compare KARO & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KARO | SNDX |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2020 | 2014 |
| Metric | KARO | SNDX |
|---|---|---|
| Price | $61.50 | $13.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $73.89 | $37.27 |
| AVG Volume (30 Days) | 66.4K | ★ 1.9M |
| Earning Date | 10-19-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | $19.78 | $82.25 |
| Revenue Next Year | $15.55 | $46.17 |
| P/E Ratio | $24.13 | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $41.25 | $12.80 |
| 52 Week High | $68.80 | $25.59 |
| Indicator | KARO | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 23.73 |
| Support Level | $60.32 | N/A |
| Resistance Level | $67.72 | $18.75 |
| Average True Range (ATR) | 2.20 | 0.70 |
| MACD | 0.19 | -0.32 |
| Stochastic Oscillator | 60.25 | 6.49 |
Karooooo Ltd is a provider of an operational intelligence platform. Through its cloud platform, the company enables fleet and asset management, fuel management, workforce management, logistics, safety, including AI-assisted video safety, compliance, risk, and environmental impact management. Its segments are: Cartrack, which generates the majority of revenue, provides an operational intelligence platform that maximizes the value of transportation, operations, and workflow data through insightful real-time data analytics to connected vehicles and equipment, and Karooooo Logistics provides a software application enabling the management of last-mile B2B delivery and general operational logistics (Delivery-as-a-Service or DaaS). It generates the majority of its revenue from South Africa.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.